The Seasonal Allergic Rhinitis drugs in development market research report provides comprehensive information on the therapeutics under development for Seasonal Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Seasonal Allergic Rhinitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Seasonal Allergic Rhinitis and features dormant and discontinued products.
GlobalData tracks 24 drugs in development for Seasonal Allergic Rhinitis by 22 companies/universities/institutes. The top development phase for Seasonal Allergic Rhinitis is phase ii with nine drugs in that stage. The Seasonal Allergic Rhinitis pipeline has 23 drugs in development by companies and one by universities/ institutes. Some of the companies in the Seasonal Allergic Rhinitis pipeline products market are: Inimmune, Regeneron Pharmaceuticals and Paradigm Biopharmaceuticals.
The key targets in the Seasonal Allergic Rhinitis pipeline products market include Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1), Histamine H1 Receptor (HRH1), and Interleukin 4 Receptor Subunit Alpha (CD124 or IL4R).
See Also:
The key mechanisms of action in the Seasonal Allergic Rhinitis pipeline product include Histamine H1 Receptor (HRH1) Antagonist with four drugs in Phase III. The Seasonal Allergic Rhinitis pipeline products include nine routes of administration with the top ROA being Nasal and six key molecule types in the Seasonal Allergic Rhinitis pipeline products market including Small Molecule, and Monoclonal Antibody.
Seasonal Allergic Rhinitis overview
Seasonal allergic rhinitis (SAR), commonly referred to as hay fever, is an inflammatory condition affecting the upper airways in response to exposure to airborne allergens, typically pollen from trees, grasses, and weeds, particularly prevalent in certain seasons. This condition manifests in sensitized individuals, giving rise to symptoms such as sneezing, nasal congestion, a runny nose, itchy or watery eyes, and fatigue. SAR involves an immune system response, with the release of histamines and other chemicals triggered by exposure to allergens. While SAR itself doesn’t pose a serious health threat, its impact on the quality of life for those affected can be substantial. Management strategies often include allergen avoidance, the use of over-the-counter or prescription antihistamines, nasal corticosteroids, and, in severe cases, allergen immunotherapy.
For a complete picture of Seasonal Allergic Rhinitis’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
